ARA-290 (Cibinetide)
Nonerythropoietic erythropoietin-derived peptide (cibinetide) investigated for neuropathy and tissue protection.
Technical Dossier
Batch / Lot Number
—
Testing Status
—
Testing Laboratory
—
Test Date
—
Classification
Nonerythropoietic erythropoietin-derived peptide (cibinetide)
Mechanism / Biological Target
Research Areas
Research Overview
Laboratory Storage & Handling
References
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin
Clinical study (metabolic control and neuropathy), 2014.
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis
Phase II clinical trials, 2014.
- The erythropoietin-derived peptide ARA290 reverses mechanical allodynia
Pain study, 2013.
- Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density (NCT02039687)
ClinicalTrials.gov phase II (sarcoidosis small fiber neuropathy).
Available Documentation
- Certificate of AnalysisPending / Not yet available
For Research Use Only
Compounds referenced on Peptide Underground are intended for laboratory and research purposes only. They are not intended to diagnose, treat, cure, or prevent any disease and are not intended for human consumption.